interactions

Last reviewed 01/2018

  • the manufacturer recommends that reboxetine should be used with caution in patients prescribed medication that is metabolised by CYP3A4 e.g. antiarrhythmic drugs (1). Also reboxetine should not prescribed with drugs that may inhibit CYP3A4 e.g. azole antifungal drugs

  • should not be used concomitantly with monoamine oxidase inhibitors

  • there is a risk of postural hypotension in patients taking antihypertensive medication

Check the summary of product characteristics before prescribing this drug.

Reference:

  • Drug and Therapeutics Bulletin (1998), 36 (11), 82-4.